HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A founder AGL mutation causing glycogen storage disease type IIIa in Inuit identified through whole-exome sequencing: a case series.

AbstractBACKGROUND:
Glycogen storage disease type III is caused by mutations in both alleles of the AGL gene, which leads to reduced activity of glycogen-debranching enzyme. The clinical picture encompasses hypoglycemia, with glycogen accumulation leading to hepatomegaly and muscle involvement (skeletal and cardiac). We sought to identify the genetic cause of this disease within the Inuit community of Nunavik, in whom previous DNA sequencing had not identified such mutations.
METHODS:
Five Inuit children with a clinical and biochemical diagnosis of glycogen storage disease type IIIa were recruited to undergo genetic testing: 2 underwent whole-exome sequencing and all 5 underwent Sanger sequencing to confirm the identified mutation. Selected DNA regions near the AGL gene were also sequenced to identify a potential founder effect in the community. In addition, control samples from 4 adults of European descent and 7 family members of the affected children were analyzed for the specific mutation by Sanger sequencing.
RESULTS:
We identified a homozygous frame-shift deletion, c.4456delT, in exon 33 of the AGL gene in 2 children by whole-exome sequencing. Confirmation by Sanger sequencing showed the same mutation in all 5 patients, and 5 family members were found to be carriers. With the identification of this mutation in 5 probands, the estimated prevalence of genetically confirmed glycogen storage disease type IIIa in this region is among the highest worldwide (1:2500). Despite identical mutations, we saw variations in clinical features of the disease.
INTERPRETATION:
Our detection of a homozygous frameshift mutation in 5 Inuit children determines the cause of glycogen storage disease type IIIa and confirms a founder effect.
AuthorsIsabelle Rousseau-Nepton, Minoru Okubo, Rosemarie Grabs, FORGE Canada Consortium, John Mitchell, Constantin Polychronakos, Celia Rodd
JournalCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne (CMAJ) Vol. 187 Issue 2 Pg. E68-E73 (Feb 03 2015) ISSN: 1488-2329 [Electronic] Canada
PMID25602008 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2015 Canadian Medical Association or its licensors.
Chemical References
  • Glycogen Debranching Enzyme System
Topics
  • Canada
  • Case-Control Studies
  • Child, Preschool
  • Cohort Studies
  • DNA Mutational Analysis
  • Exome (genetics)
  • Female
  • Founder Effect
  • Glycogen Debranching Enzyme System (genetics)
  • Glycogen Storage Disease Type III (diagnosis, ethnology, genetics)
  • Humans
  • Infant
  • Inuit (genetics)
  • Male
  • Mutation (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: